Triaxone® — Ceftriaxone for Injection 500 mg & 1 g I.M. / I.V.
1- Disclaimer
This information is intended for educational and professional reference purposes and does not replace the official product information, medical diagnosis, clinical judgment, antimicrobial-susceptibility data, or advice from a qualified physician or pharmacist. Ceftriaxone is a prescription antibacterial medicine that should be administered only under appropriate medical supervision.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Dosage, route of administration, duration of treatment, diluent selection, and compatibility requirements may differ according to indication, patient characteristics, local resistance patterns, national treatment guidelines, and the exact locally marketed presentation. The current package insert supplied with the product should always be checked before preparation or administration.
2- Summary
Triaxone® contains ceftriaxone, a bactericidal, third-generation cephalosporin antibacterial agent for parenteral administration. Ceftriaxone inhibits bacterial cell-wall synthesis and has activity against many susceptible Gram-positive and Gram-negative organisms.
Its relatively long elimination half-life—approximately eight hours in healthy adults—allows once-daily administration for many infections, although some severe infections may require higher doses or division of the daily dose.
Ceftriaxone is used for serious and susceptible bacterial infections including pneumonia, bacterial meningitis, complicated urinary tract infections, intra-abdominal infections, skin and soft-tissue infections, bone and joint infections, bacteraemia associated with susceptible infections, gonorrhoea, and selected other infections. It is also used for surgical prophylaxis in appropriate circumstances.
Ceftriaxone should not be used for viral infections, and bacterial cultures and susceptibility testing should be obtained whenever clinically appropriate.
3- Brand Name
Triaxone®
The supplied product information identifies Triaxone as ceftriaxone for injection manufactured by Tabuk Pharmaceutical Manufacturing Company.
The current Tabuk Pharmaceuticals product catalogue also identifies TRIAXONE as a ceftriaxone product in the anti-infective category and lists 0.5-g and 1-g IM/IV presentations in several markets.
4- Category
- Prescription antibacterial medicine.
- Beta-lactam antibiotic.
- Third-generation cephalosporin.
- Pharmacotherapeutic group: antibacterials for systemic use, third-generation cephalosporins.
- ATC code for ceftriaxone: J01DD04.
5- Active Ingredient
Ceftriaxone, supplied as ceftriaxone sodium.
Each vial contains ceftriaxone sodium equivalent to the labelled quantity of ceftriaxone.
The lidocaine solution supplied with certain IM presentations is a diluent for intramuscular administration, not the antibacterial active ingredient.
6- Pharmaceutical Form & Strength
Triaxone is supplied as sterile ceftriaxone powder for preparation of an injectable solution.
Presentations documented for the product include:
Triaxone 500 mg I.M.
- Vial containing sterile ceftriaxone sodium equivalent to 500 mg ceftriaxone.
- The documented IM pack includes 1% lidocaine hydrochloride solution as diluent.
Triaxone 1 g I.M.
- Vial containing sterile ceftriaxone sodium equivalent to 1 g ceftriaxone.
- The documented IM pack includes 1% lidocaine hydrochloride solution as diluent.
Triaxone 1 g I.V.
- Vial containing sterile ceftriaxone sodium equivalent to 1 g ceftriaxone.
- The documented IV pack includes Sterile Water for Injection.
Current 2026 Egyptian medicine listings continue to report Triaxone 500 mg IM, Triaxone 1 g IM, and Triaxone 1 g IV as Tabuk Pharmaceutical Manufacturing Company products.
Availability, packaging, price, and registration status can change and should be verified from the current Egyptian package and official regulatory records.
7- Manufacturer & Marketing Authorization Holder
Manufacturer:
Tabuk Pharmaceutical Manufacturing Company
Tabuk, Saudi Arabia.
The supplied Triaxone product information identifies Tabuk Pharmaceutical Manufacturing Company, Saudi Arabia, as the manufacturer.
Current Egyptian market records also identify Tabuk Pharmaceutical Manufacturing Company as the producer/marketing company for the Egyptian Triaxone presentations.
The exact current Egyptian marketing-authorization information and registration details should be verified against the current Egyptian Drug Authority record and the locally marketed carton/package insert.
8- Mechanism of Action
Ceftriaxone is a bactericidal beta-lactam antibiotic.
It binds to bacterial penicillin-binding proteins (PBPs) and inhibits the final stages of peptidoglycan synthesis required for formation of a structurally intact bacterial cell wall.
Disruption of cell-wall synthesis results in loss of bacterial cell-wall integrity and ultimately bacterial lysis and death.
Important mechanisms of bacterial resistance include:
- Production of beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), carbapenemases, and clinically relevant AmpC enzymes.
- Changes in penicillin-binding proteins.
- Reduced permeability of the bacterial outer membrane.
- Efflux mechanisms.
9- Spectrum of Activity
The antibacterial spectrum of ceftriaxone depends on the organism, site of infection, local resistance patterns, and susceptibility-test result.
Organisms that may be susceptible include:
Gram-positive organisms
- Methicillin-susceptible Staphylococcus aureus.
- Susceptible coagulase-negative staphylococci.
- Streptococcus pyogenes.
- Streptococcus agalactiae.
- Streptococcus pneumoniae.
- Viridans-group streptococci.
Gram-negative organisms
- Haemophilus influenzae.
- Haemophilus parainfluenzae.
- Moraxella catarrhalis.
- Neisseria meningitidis.
- Neisseria gonorrhoeae.
- Proteus mirabilis.
- Some other susceptible Enterobacterales.
Ceftriaxone also has clinically relevant activity in appropriate circumstances against Treponema pallidum and Borrelia burgdorferi.
Resistance can be a major problem with organisms such as Escherichia coli, Klebsiella species, Enterobacter species, Citrobacter freundii, Morganella morganii, Serratia marcescens, Bacteroides species and others. Local susceptibility data are therefore important.
Important organisms not reliably covered by ceftriaxone include:
- Methicillin-resistant staphylococci (MRSA/MR-CoNS).
- Enterococcus species.
- Listeria monocytogenes.
- Pseudomonas aeruginosa.
- Acinetobacter baumannii.
- Stenotrophomonas maltophilia.
- Clostridioides difficile.
- Mycoplasma species.
- Chlamydia/Chlamydophila species.
- Legionella species.
- Ureaplasma urealyticum.
ESBL-producing Enterobacterales should not be assumed to be susceptible to ceftriaxone.
Because resistance varies geographically and over time, microbiological susceptibility testing and local antimicrobial guidelines should take precedence over fixed organism lists.
10- Pharmacokinetics
Absorption
After IM administration, ceftriaxone is well absorbed. Systemic exposure following IM administration is essentially comparable to that achieved after an equivalent IV dose.
After a 1-g IM dose, peak plasma concentrations are reached approximately 2–3 hours after administration.
Distribution
Ceftriaxone distributes widely into tissues and body fluids, including lung, bone, biliary tract, pleural fluid, synovial fluid and, under appropriate circumstances, cerebrospinal fluid.
Penetration into cerebrospinal fluid is greater when the meninges are inflamed.
Ceftriaxone crosses the placenta and is present in human milk in low concentrations.
Protein binding
Ceftriaxone is reversibly and concentration-dependently bound to albumin. Binding is approximately 95% at lower plasma concentrations and decreases as concentration increases.
Metabolism
Ceftriaxone is not extensively metabolized systemically. Drug reaching the intestine may be converted to inactive metabolites by intestinal flora.
Elimination
Approximately:
- 50–60% is excreted unchanged in urine.
- 40–50% is excreted unchanged through bile.
The elimination half-life in healthy adults is approximately 8 hours.
The half-life is prolonged in neonates and generally longer in elderly patients.
Ceftriaxone is not effectively removed by haemodialysis or peritoneal dialysis.
11- Indications
Ceftriaxone may be used for treatment of infections caused by susceptible organisms, including:
- Bacterial meningitis.
- Community-acquired pneumonia.
- Hospital-acquired pneumonia.
- Acute otitis media in selected circumstances.
- Intra-abdominal infections.
- Complicated urinary tract infections, including pyelonephritis.
- Bone and joint infections.
- Complicated skin and soft-tissue infections.
- Gonorrhoea.
- Syphilis in appropriate treatment regimens.
- Bacterial endocarditis.
- Bacteraemia occurring in association with susceptible infections.
- Selected cases of acute exacerbation of chronic obstructive pulmonary disease.
- Disseminated Lyme borreliosis where applicable.
- Management of febrile neutropenic patients when a bacterial infection is suspected, normally as part of an appropriate antimicrobial strategy.
- Pre-operative prophylaxis of surgical-site infection in appropriate procedures.
Ceftriaxone may need to be combined with another antimicrobial when organisms outside its spectrum are likely, particularly in polymicrobial infections.
Antibiotic selection should be guided by local treatment guidelines and antimicrobial-resistance data.
12- Administration
General principles
The dose depends on:
- Severity and site of infection.
- Suspected or documented organism.
- Antimicrobial susceptibility.
- Patient age and weight.
- Renal and hepatic function.
- Local treatment guidelines.
Adults and children ≥12 years and ≥50 kg
For many susceptible infections, the usual dose is:
1–2 g once daily.
More severe infections may require:
2–4 g per day.
When daily doses exceed 2 g, administration every 12 hours may be considered according to the indication and guideline.
Bacterial meningitis
Higher ceftriaxone doses are required. Current product information allows 2–4 g/day in adults, with higher daily doses potentially divided every 12 hours.
Paediatric dosing is commonly in the range of 80–100 mg/kg/day, maximum 4 g/day, depending on age and local meningitis guidance.
Children 15 days to 12 years weighing <50 kg
Depending on indication:
- 50–80 mg/kg once daily for a number of common severe infections.
- 50–100 mg/kg once daily, maximum 4 g, for selected severe infections.
- 80–100 mg/kg once daily, maximum 4 g, for bacterial meningitis.
- 100 mg/kg once daily, maximum 4 g, may be used for bacterial endocarditis according to current SmPC guidance.
Children weighing 50 kg or more generally receive the adult dose.
Neonates 0–14 days
Depending on the indication:
20–50 mg/kg once daily.
The maximum daily dose should generally not exceed 50 mg/kg in this age group. Important neonatal contraindications must be observed.
Gonorrhoea
Current treatment recommendations should be followed rather than historical dosing schedules.
For uncomplicated gonorrhoea, the current CDC regimen is:
- Ceftriaxone 500 mg IM once for persons weighing less than 150 kg.
- Ceftriaxone 1 g IM once for persons weighing 150 kg or more.
If chlamydial infection has not been excluded, appropriate treatment for chlamydia should also be given according to current STI guidance.
Local Egyptian/national STI recommendations should take precedence where they differ.
Surgical prophylaxis
Ceftriaxone is generally administered 30–90 minutes before surgery when it is an appropriate prophylactic antibacterial.
Duration
Treatment duration depends on infection, clinical response, organism and guideline. Fixed treatment durations should not be applied indiscriminately.
13- Method of Preparation
Preparation must be performed using aseptic technique and the exact instructions provided with the marketed presentation.
Triaxone 500 mg I.M.
The supplied Triaxone instructions specify reconstitution of the 500-mg vial with 2 mL of the supplied 1% lidocaine hydrochloride solution.
Triaxone 1 g I.M.
Reconstitute the 1-g vial with 3.5 mL of 1% lidocaine hydrochloride solution.
Administer as a deep intramuscular injection into a large muscle.
No more than approximately 1 g should normally be injected into one IM site; larger IM doses should be divided between sites.
A ceftriaxone solution prepared with lidocaine must NEVER be administered intravenously.
Contraindications and precautions applicable to lidocaine must be checked before its use.
Triaxone 1 g I.V.
The documented Triaxone preparation is:
1 g ceftriaxone + 10 mL Sterile Water for Injection.
Current ceftriaxone SmPCs recommend administration of a slow IV injection over approximately 5 minutes, preferably into a large vein, when IV injection is used.
I.V. infusion
Ceftriaxone may also be administered by IV infusion using an appropriate calcium-free compatible solution, generally over at least 30 minutes.
In neonates, IV doses should be administered over approximately 60 minutes to reduce the potential risk of bilirubin encephalopathy.
Calcium-containing solutions
Do not use calcium-containing diluents such as Ringer's solution or Hartmann's solution to reconstitute or dilute ceftriaxone.
Ceftriaxone and calcium-containing IV solutions must not be mixed or administered simultaneously through the same line because ceftriaxone-calcium precipitation may occur.
For patients older than 28 days, ceftriaxone and calcium-containing IV solutions may be administered sequentially when appropriate if separate lines are used or the infusion line is replaced or thoroughly flushed with a compatible fluid between administrations.
Only clear solutions without visible particles should be administered.
14- Contraindications
Ceftriaxone is contraindicated in patients with:
- Known hypersensitivity to ceftriaxone or another cephalosporin.
- A history of severe immediate hypersensitivity, such as anaphylaxis, to another beta-lactam antibacterial where clinically applicable.
Important neonatal contraindications include:
- Premature neonates up to a postmenstrual age of approximately 41 weeks under current European product information.
- Full-term neonates ≤28 days with hyperbilirubinaemia, jaundice, hypoalbuminaemia or acidosis where bilirubin binding may be impaired.
- Neonates ≤28 days who require, or are expected to require, intravenous calcium-containing treatment or calcium-containing infusions such as parenteral nutrition.
When lidocaine is used to prepare an IM dose, all contraindications to lidocaine must also be excluded.
Ceftriaxone containing lidocaine must never be administered intravenously.
15- Warnings & Precautions
Serious hypersensitivity
Severe and occasionally fatal hypersensitivity reactions, including anaphylaxis, may occur. Treatment must be stopped immediately and appropriate emergency management instituted if a severe reaction develops.
Severe skin reactions
Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS have been reported.
Ceftriaxone-calcium precipitation
The greatest risk occurs in neonates, in whom fatal precipitation in the lungs and kidneys has been reported.
Ceftriaxone must not be mixed with calcium-containing IV solutions.
Immune haemolytic anaemia
Severe and occasionally fatal immune-mediated haemolytic anaemia has occurred in both adults and children. Unexplained anaemia requires prompt assessment and possible discontinuation.
Clostridioides difficile-associated diarrhoea
Antibiotic-associated colitis can occur during or after treatment and may range from mild diarrhoea to life-threatening colitis.
Neurological toxicity
Encephalopathy, altered consciousness, myoclonus and seizures have been reported, particularly in elderly patients and patients with significant renal impairment or pre-existing CNS disorders.
Gallbladder precipitation
Ceftriaxone-calcium precipitates may produce sonographic appearances resembling gallstones (“biliary pseudolithiasis”). These usually disappear after treatment ends but occasionally cause symptoms.
Pancreatitis
Rare cases, sometimes associated with biliary sludge or obstruction, have been reported.
Urinary precipitation and renal stones
Reversible renal/urinary ceftriaxone precipitation can occur, particularly in children receiving high doses or in patients with dehydration and other risk factors.
Prolonged treatment
Complete blood counts should be monitored periodically during prolonged treatment.
Superinfection
Prolonged antibacterial use can result in overgrowth of organisms not susceptible to ceftriaxone.
Laboratory-test interference
Ceftriaxone can interfere with:
- Direct Coombs testing.
- Some galactosaemia tests.
- Non-enzymatic urine-glucose testing.
- Certain blood-glucose monitoring systems.
Appropriate alternative laboratory methods may be required.
16- Drug Interactions
Calcium-containing IV solutions
The most clinically important compatibility issue is ceftriaxone-calcium precipitation.
Calcium-containing IV diluents must not be used for ceftriaxone preparation, and ceftriaxone must not be administered simultaneously with calcium-containing IV solutions.
Vitamin-K antagonist anticoagulants
Concurrent use with oral vitamin-K antagonists may increase anticoagulant effect and bleeding risk. INR monitoring may be required during and after treatment.
Aminoglycosides
When an aminoglycoside is also required, appropriate renal-function and aminoglycoside-level monitoring should be performed where indicated.
Ceftriaxone and aminoglycosides should not be physically mixed in the same solution.
Physical incompatibility
Ceftriaxone is reported to be physically incompatible in admixture with several medicines, including:
- Vancomycin.
- Aminoglycosides.
- Fluconazole.
- Amsacrine.
Separate administration should be used when required.
Chloramphenicol
In-vitro antagonism has been reported between ceftriaxone and chloramphenicol, although its clinical relevance is uncertain.
Probenecid
Probenecid does not produce the major reduction in ceftriaxone elimination seen with some other beta-lactam antibiotics.
Oral calcium does not carry the same precipitation restriction as intravenous calcium.
17- Side Effects
The most commonly reported adverse effects of ceftriaxone include:
- Diarrhoea or loose stools.
- Eosinophilia.
- Leukopenia.
- Thrombocytopenia.
- Rash.
- Increased hepatic enzymes.
Other reported reactions include:
Gastrointestinal
- Nausea.
- Vomiting.
- Stomatitis.
- Glossitis.
Blood and coagulation
- Granulocytopenia.
- Anaemia.
- Agranulocytosis.
- Coagulopathy.
- Immune haemolytic anaemia.
Skin and hypersensitivity
- Pruritus.
- Urticaria.
- Rash.
- Anaphylaxis.
- Anaphylactic shock.
- Stevens-Johnson syndrome.
- Toxic epidermal necrolysis.
- DRESS.
- Acute generalized exanthematous pustulosis.
Nervous system
- Headache.
- Dizziness.
- Encephalopathy.
- Convulsions.
Hepatobiliary
- Increased liver enzymes.
- Gallbladder ceftriaxone-calcium precipitation.
- Hepatitis or cholestatic hepatitis in rare/post-marketing cases.
Renal and urinary
- Haematuria.
- Increased creatinine.
- Oliguria.
- Reversible urinary ceftriaxone precipitation.
Local reactions
- Injection-site pain.
- Phlebitis following IV administration.
Other important effects
- Clostridioides difficile-associated colitis.
- Pancreatitis.
- Superinfection.
- Genital fungal infection.
- Fever and chills.
Any serious, severe or unexpected adverse reaction requires medical assessment.
18- Use in Special Populations
Pregnancy
Ceftriaxone crosses the placenta.
Current prescribing information no longer relies on the historical FDA “Pregnancy Category B” classification system.
Available human pregnancy data are limited, while animal studies have not demonstrated relevant direct reproductive toxicity. Ceftriaxone may be used during pregnancy when the expected clinical benefit outweighs potential risk, particularly after consideration of infection severity and alternative treatments.
Breast-feeding
Ceftriaxone is excreted into human milk in low concentrations.
Clinically important exposure in a breast-fed infant is generally not expected, but diarrhoea, mucosal fungal overgrowth or sensitization cannot be completely excluded.
The benefit of breast-feeding and the clinical need for ceftriaxone should both be considered.
Neonates
Special caution is essential because ceftriaxone can displace bilirubin from albumin.
It is contraindicated in certain premature neonates and in full-term neonates with conditions that increase the risk of bilirubin encephalopathy.
It is also contraindicated in neonates ≤28 days requiring IV calcium-containing treatment.
Children
Paediatric dosing is weight-based.
IV doses of 50 mg/kg or more in infants and children should generally be given by infusion rather than rapid IV injection.
Elderly
Routine dose reduction solely because of age is generally unnecessary when renal and hepatic function are satisfactory.
Neurological adverse effects should nevertheless be considered particularly in elderly patients with severe renal impairment.
Renal impairment
Dose reduction is generally unnecessary when hepatic function is intact.
In severe/preterminal renal failure with creatinine clearance below approximately 10 mL/min, current SmPC guidance recommends that the daily ceftriaxone dose generally not exceed 2 g.
Ceftriaxone is not substantially removed by haemodialysis, and an additional post-dialysis dose is normally unnecessary.
Hepatic impairment
Dose reduction is usually unnecessary in mild or moderate hepatic impairment when renal function is satisfactory.
Patients with simultaneous severe renal and hepatic impairment require close clinical monitoring.
19- Storage Conditions
According to the Triaxone product information supplied:
- Store the unopened product at room temperature, 15–30°C.
- Keep the vial in its carton until use.
- Do not use after the expiry date.
- Do not use a product showing signs of deterioration.
The stability of ceftriaxone after reconstitution depends on the precise formulation, concentration, diluent, container, temperature and microbiological preparation conditions.
For this reason, the current package-specific instructions should be followed. From a microbiological perspective, freshly prepared solutions should generally be used promptly unless preparation and storage have occurred under appropriately validated aseptic conditions.
Keep medicines out of the reach of children.
20- Additional Sections
Antimicrobial Stewardship
Triaxone should be used only for infections that are proven or strongly suspected to be bacterial and susceptible to ceftriaxone.
Unnecessary use contributes to antimicrobial resistance.
Whenever possible:
- Obtain appropriate cultures before starting treatment.
- Review microbiological susceptibility results.
- Narrow or modify therapy when the causative organism becomes known.
- Follow local antimicrobial-resistance patterns and stewardship policies.
Compatibility
Ceftriaxone must not be mixed with calcium-containing IV solutions.
When combination antibacterial treatment is required, drugs that are physically incompatible with ceftriaxone must be administered separately.
Overdose
Possible overdose manifestations include nausea, vomiting, diarrhoea and neurological toxicity.
There is no specific antidote.
Treatment is supportive and symptomatic.
Haemodialysis and peritoneal dialysis do not effectively remove ceftriaxone.
Driving and Operating Machinery
Ceftriaxone does not ordinarily produce major impairment, but dizziness or neurological adverse effects can occur. Affected patients should avoid driving or operating machinery.
21- Frequently Asked Questions (FAQ)
Q1: What is Triaxone?
Triaxone is a brand of ceftriaxone, a third-generation cephalosporin antibiotic administered by IM or IV injection.
Q2: Can Triaxone treat colds or influenza?
No. Colds and influenza are viral diseases. Ceftriaxone treats susceptible bacterial infections and should not be used unnecessarily.
Q3: Is ceftriaxone normally given once daily?
Often, yes. Its long half-life permits once-daily dosing for many infections. Severe infections such as meningitis or endocarditis may require higher doses and, in some circumstances, division of the daily dose.
Q4: Can the lidocaine supplied with the IM presentation be used intravenously?
No. A ceftriaxone solution prepared with lidocaine must never be administered intravenously. Lidocaine-containing diluent is intended only for appropriate IM preparation.
Q5: Can Triaxone be mixed with Ringer's or Hartmann's solution?
No. These solutions contain calcium and should not be used to reconstitute or dilute ceftriaxone because ceftriaxone-calcium precipitation may occur.
Q6: Can calcium-containing IV therapy ever be given to a patient receiving ceftriaxone?
In neonates ≤28 days who require IV calcium, ceftriaxone is contraindicated.
In patients older than 28 days, ceftriaxone and calcium-containing IV solutions must not be mixed or infused simultaneously through the same line, but they may generally be given sequentially if appropriate precautions are taken and the infusion line is replaced or thoroughly flushed with compatible solution.
Q7: Is Triaxone active against Pseudomonas aeruginosa?
Ceftriaxone should not be relied upon for Pseudomonas aeruginosa. Current ceftriaxone susceptibility information lists P. aeruginosa among organisms intrinsically resistant to ceftriaxone.
Q8: Is ceftriaxone effective against MRSA?
No. Methicillin-resistant staphylococci should be regarded as resistant to ceftriaxone.
Q9: What is the current ceftriaxone dose for uncomplicated gonorrhoea?
Current CDC guidance recommends 500 mg IM once for persons weighing less than 150 kg and 1 g IM once for persons weighing 150 kg or more. Appropriate treatment for chlamydia should also be provided if infection has not been excluded. Local national guidance should also be followed.
Q10: Does renal impairment always require ceftriaxone dose reduction?
No. Because ceftriaxone is eliminated through both urine and bile, routine adjustment is often unnecessary when only renal function is impaired. Severe renal failure and combined severe renal/hepatic dysfunction require additional caution and monitoring.
Q11: Can ceftriaxone cause gallstones?
Ceftriaxone-calcium precipitates can occur in the gallbladder and may appear like gallstones on ultrasound. They are usually reversible after ceftriaxone is discontinued.
Q12: Can ceftriaxone be used during pregnancy?
It may be used when medically indicated after a clinician considers the expected benefit and possible risks. The historical “Pregnancy Category B” designation should not be treated as a current pregnancy-risk classification.
22- References
- Triaxone® product information — Tabuk Pharmaceutical Manufacturing Company. Product-specific composition, IM/IV presentations, reconstitution instructions, storage conditions and manufacturer information.
- Tabuk Pharmaceuticals — TRIAXONE official product page. Confirms TRIAXONE brand, ceftriaxone active ingredient, anti-infective category and currently displayed presentations.
- Ceftriaxone 1 g Summary of Product Characteristics, electronic Medicines Compendium (emc), updated August 2026. Current information on indications, doses, contraindications, warnings, interactions, pharmacology, adverse effects, special populations, preparation and compatibility.
- Ceftriaxone 1 g Summary of Product Characteristics, hameln pharma, updated 2026. Current preparation, administration, neonatal and calcium-related safety information.
- U.S. National Library of Medicine — DailyMed, Ceftriaxone for Injection. Prescribing information covering serious hypersensitivity, neurological adverse reactions, C. difficile-associated diarrhoea, haemolytic anaemia, gallbladder abnormalities, pancreatitis and drug incompatibilities.
- U.S. Centers for Disease Control and Prevention — Gonococcal Infections Among Adolescents and Adults, STI Treatment Guidelines. Current ceftriaxone treatment regimen for uncomplicated gonorrhoea.
- Current Egyptian medicine-market records (2026). Listings identify Triaxone 500 mg IM, 1 g IM and 1 g IV presentations containing ceftriaxone and manufactured by Tabuk Pharmaceutical Manufacturing Company.
Triaxone® (ceftriaxone) is a prescription antibacterial medicine. Selection, dose, preparation, route and duration of treatment must be determined by qualified healthcare professionals according to the infection, patient characteristics, microbiological susceptibility and current local clinical guidelines.